13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Preparation of PLGA-chitosan based nanocarriers for enhancing antibacterial effect of ciprofloxacin in root canal infection

      research-article
      a , b , c , d , e
      Drug Delivery
      Taylor & Francis
      PLGA, chitosan, nanocarriers, ciprofloxacin, root canal

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this study is to prepare and evaluate the antibacterial and antibiofilm activity of ciprofloxacin (CIP) loaded PLGA nanoparticles (F2) and CIP-PLGA nanoparticles coated with chitosan (F3) versus ciprofloxacin solution (Fl) as a control on Enterococcus faecalis. F2 was prepared using double emulsion evaporation technique then coated with chitosan (F3). The prepared F2 and F3 were evaluated for size, surface charge, encapsulation efficiency, morphology and in vitro release. F1, F2, F3, and Chitosan (CS) were assessed in vitro using agar diffusion technique and biofilm inhibition assay. Finally, biofilm inhibition on teeth using Colony Forming Unit (CFU) was implemented with different concentrations of the three formulae. The results revealed that F2 is 202.9 nm with a negative charge −0.0254 mv, while F3 is 339.6 nm with a positive charge +28.5 mv. The encapsulation efficiency of F2, and F3 was 64% and 78% respectively. The amount released was 92.62% and 78.3% for F2 and F3, respectively, after 72 h, while F1 showed 100% released in the first hour. CS, F1, F2, and F3, showed antibacterial effect with inhibition zone of 12 mm, 22 mm, 20 mm, and 32 mm respectively. Biofilm inhibition of F1, F2, and F3 were 60%, 74%, and 91.8%, respectively. F3 colony count was less than F2, and F1 in all concentrations. It can be concluded that F3 had proven to exhibit potential antibacterial and antibiofilm activity in a controlled release pattern consequently, they can be used as an intra-canal medication.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Nanoparticle-based targeted drug delivery.

          Nanotechnology could be defined as the technology that has allowed for the control, manipulation, study, and manufacture of structures and devices in the "nanometer" size range. These nano-sized objects, e.g., "nanoparticles", take on novel properties and functions that differ markedly from those seen from items made of identical materials. The small size, customized surface, improved solubility, and multi-functionality of nanoparticles will continue to open many doors and create new biomedical applications. Indeed, the novel properties of nanoparticles offer the ability to interact with complex cellular functions in new ways. This rapidly growing field requires cross-disciplinary research and provides opportunities to design and develop multifunctional devices that can target, diagnose, and treat devastating diseases such as cancer. This article presents an overview of nanotechnology for the biologist and discusses the attributes of our novel XPclad((c)) nanoparticle formulation that has shown efficacy in treating solid tumors, single dose vaccination, and oral delivery of therapeutic proteins.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Biodegradation, biodistribution and toxicity of chitosan.

            Chitosan is a natural polysaccharide that has attracted significant scientific interest during the last two decades. It is a potentially biologically compatible material that is chemically versatile (-NH2 groups and various M(w)). These two basic properties have been used by drug delivery and tissue engineering scientists to create a plethora of formulations and scaffolds that show promise in healthcare. Despite the high number of published studies, chitosan is not approved by the FDA for any product in drug delivery, and as a consequence very few biotech companies are using this material. This review will aim to provide information on these biological properties that affect chitosan's safe use in drug delivery. The term "Chitosan" represents a large group of structurally different chemical entities that may show different biodistribution, biodegradation and toxicological profiles. Here we aim to review research in this area and critically discuss chitosan's potential to be used as a generally regarded as safe (GRAS) material. 2009 Elsevier B.V. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Recent applications of PLGA based nanostructures in drug delivery

                Bookmark

                Author and article information

                Journal
                Drug Deliv
                Drug Deliv
                IDRD
                idrd20
                Drug Delivery
                Taylor & Francis
                1071-7544
                1521-0464
                2020
                13 December 2019
                : 27
                : 1
                : 26-39
                Affiliations
                [a ]Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE) , El Sherouk City, Egypt;
                [b ]Chemotherapeutic Unit, Mansoura University Hospitals , Mansoura, Egypt;
                [c ]Department of Medical Science, Faculty of Dentistry, The British University in Egypt (BUE) , El Sherouk City, Egypt;
                [d ]Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University , Cairo, Egypt;
                [e ]Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6th University , Cairo, Egypt
                Author notes
                CONTACT Mona G. Arafa mona.arafa@ 123456bue.edu.eg Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt (BUE) , El Sherouk City, Cairo 11837, Egypt
                Article
                1701140
                10.1080/10717544.2019.1701140
                6968620
                31833443
                54d5a94a-d0be-46c7-b477-47bc93644183
                © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 15 October 2019
                : 28 November 2019
                : 02 December 2019
                Page count
                Figures: 10, Tables: 4, Pages: 14, Words: 7418
                Categories
                Research Article

                Pharmacology & Pharmaceutical medicine
                plga,chitosan,nanocarriers,ciprofloxacin,root canal
                Pharmacology & Pharmaceutical medicine
                plga, chitosan, nanocarriers, ciprofloxacin, root canal

                Comments

                Comment on this article